Roche to buy U.S. biotech group Adheron Therapeutics
October 09, 2015 at 09:21 AM EDT
ZURICH, Oct 9 (Reuters) - Swiss drugmaker Roche will acquire U.S. biotech group Adheron Therapeutics in a deal worth up to $580 million that boosts its pipeline of products to treat diseases such as rheumatoid arthritis, Adheron said on Friday.
